Hartleb, Marek
3 papers on CoChatORCID 0000-0001-5301-8931
Most cited papers
- Verified
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: Interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
Younossi, Z. M., Ratziu, V., Loomba, R., Rinella, M., Anstee, Q. M., Goodman, Z., Bedossa, P., Geier, A., Beckebaum, S., Newsome, P. N., et al. (2019) · The Lancet
Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity
Cited by 1,277
- Verified
Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study
Jones, D., Boudes, P. F., Swain, M. G., Bowlus, C. L., Galambos, M. R., Bacon, B. R., Doerffel, Y., Gitlin, N., Gordon, S. C., Odin, J. A., et al. (2017) · The Lancet Gastroenterology & Hepatology
Liver Diseases and ImmunityPeroxisome Proliferator-Activated Receptors
Cited by 191
- Verified
Common functional alterations identified in blood transcriptome of autoimmune cholestatic liver and inflammatory bowel diseases
Ostrowski, J., Goryca, K., Lazowska, I., Rogowska, A., Paziewska, A., Dabrowska, M., Ambrozkiewicz, F., Karczmarski, J., Balabas, A., Kluska, A., et al. (2019) · Scientific Reports
Liver Diseases and ImmunityInflammatory Bowel Disease
Cited by 36
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free